$VASO
VASO Corp Stock $vaso

$vaso Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000165495423004142 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$19.22M	$23.47M	$80.02M
YoY Change	13.0%	-4.2%	5.87%
Cost Of Revenue	$7.511M	$8.630M	$31.54M
YoY Change	3.71%	-2.22%	-2.8%
Gross Profit	$11.71M	$14.84M	$48.48M
YoY Change	19.89%	-5.32%	12.4%
Gross Profit Margin	60.92%	63.23%	60.59%
Selling, General & Admin	$11.14M	$11.26M	$40.84M
YoY Change	11.44%	2.85%	5.83%
% of Gross Profit	95.16%	75.87%	84.25%
Research & Development	$157.0K	$183.0K	$605.0K
YoY Change	28.69%	-85.75%	-64.85%
% of Gross Profit	1.34%	1.23%	1.25%
Depreciation & Amortization	$273.0K	$347.0K	$1.923M
YoY Change	-39.74%	-83.41%	-49.92%
% of Gross Profit	2.33%	2.34%	3.97%
Operating Expenses	$11.30M	$11.44M	$41.45M
YoY Change	11.65%	-6.45%	2.81%
Operating Profit	$410.0K	$3.398M	$7.033M
YoY Change	-215.82%	-1.31%	149.49%
Interest Expense	$55.00K	$41.00K	$99.00K
YoY Change	129.17%	-161.19%	-146.26%
% of Operating Profit	13.41%	1.21%	1.41%
Other Income/Expense, Net	$54.00K		$97.00K
YoY Change	145.45%		-97.17%
Pretax Income	$464.0K	$3.439M	$7.130M
YoY Change	-239.76%	1.87%	14.06%
Income Tax	$10.00K	-$4.785M	-$4.743M
% Of Pretax Income	2.16%	-139.14%	-66.52%
Net Earnings	$454.0K	$8.224M	$11.87M
YoY Change	-231.98%	148.31%	94.64%
Net Earnings / Revenue	2.36%	35.04%	14.84%
Basic Earnings Per Share	$0.00		$0.07
Diluted Earnings Per Share	$0.00	$0.05	$0.07
COMMON SHARES
Basic Shares Outstanding	175.1M shares	175.1M shares	173.1K shares
Diluted Shares Outstanding	175.2M shares		174.7M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.25M	$20.33M	$20.33M
YoY Change	216.95%	205.46%	205.46%
Cash & Equivalents	$9.665M	$11.82M	$11.82M
Short-Term Investments	$8.588M	$8.504M	$8.504M
Other Short-Term Assets	$4.736M	$4.257M	$4.257M
YoY Change	8.47%	-6.3%	-6.3%
Inventory	$1.504M	$1.473M	$1.473M
Prepaid Expenses
Receivables	$19.42M	$22.47M	$15.52M
Other Receivables	$617.0K	$421.0K	$421.0K
Total Short-Term Assets	$38.38M	$42.00M	$42.00M
YoY Change	42.87%	51.06%	51.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.306M	$1.340M	$2.908M
YoY Change	-36.54%	-38.31%	-5.8%
Goodwill	$15.62M	$15.61M
YoY Change	-0.65%	-0.69%
Intangibles		$1.511M
YoY Change
Long-Term Investments	$811.0K	$889.0K	$889.0K
YoY Change	-23.42%	-14.77%	-14.77%
Other Assets	$5.336M	$4.726M	$9.733M
YoY Change	85.73%	93.21%	265.22%
Total Long-Term Assets	$31.12M	$30.66M	$30.66M
YoY Change	25.36%	24.83%	24.83%
TOTAL ASSETS
Total Short-Term Assets	$38.38M	$42.00M	$42.00M
Total Long-Term Assets	$31.12M	$30.66M	$30.66M
Total Assets	$69.50M	$72.66M	$72.66M
YoY Change	34.46%	38.76%	38.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.236M	$2.270M	$2.270M
YoY Change	-13.47%	-18.84%	-18.84%
Accrued Expenses	$5.976M	$12.52M	$12.52M
YoY Change	20.14%	52.96%	52.96%
Deferred Revenue
YoY Change
Short-Term Debt	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	0.0%
Long-Term Debt Due	$101.0K	$131.0K	$131.0K
YoY Change	-53.24%	-43.04%	-43.04%
Total Short-Term Liabilities	$26.22M	$31.71M	$31.71M
YoY Change	-12.49%	2.28%	2.28%
LONG-TERM LIABILITIES
Long-Term Debt	$91.00K	$111.0K	$111.0K
YoY Change	-52.85%	-53.94%	-53.94%
Other Long-Term Liabilities	$1.676M	$1.474M	$17.96M
YoY Change	52.36%	49.19%	83.09%
Total Long-Term Liabilities	$19.92M	$18.07M	$18.07M
YoY Change	85.3%	79.8%	79.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.22M	$31.71M	$31.71M
Total Long-Term Liabilities	$19.92M	$18.07M	$18.07M
Total Liabilities	$46.14M	$49.78M	$49.78M
YoY Change	13.33%	21.26%	21.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.58M	-$39.03M
YoY Change	-24.73%	-23.33%
Common Stock	$185.0K	$185.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Treasury Stock Shares	10.31M shares	10.31M shares
Shareholders Equity	$23.36M	$22.88M	$22.88M
YoY Change
Total Liabilities & Shareholders Equity	$69.50M	$72.66M	$72.66M
YoY Change	34.46%	38.76%	38.76%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$454.0K	$8.224M	$11.87M
YoY Change	-231.98%	148.31%	94.64%
Depreciation, Depletion And Amortization	$273.0K	$347.0K	$1.923M
YoY Change	-39.74%	-83.41%	-49.92%
Cash From Operating Activities	-$1.941M	$1.740M	$14.42M
YoY Change	210.56%	-26.61%	84.47%
INVESTING ACTIVITIES
Capital Expenditures	$148.0K	$119.0K	$566.0K
YoY Change	-175.9%	-347.92%	36.39%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$3.002M	-$7.851M
YoY Change	-100.0%		-5165.16%
Cash From Investing Activities	-$148.0K	-$3.121M	-$8.417M
YoY Change	-58.07%	6402.08%	3137.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$48.00K	-53.00K	-$230.0K
YoY Change	-22.58%	-97.86%	-97.24%
NET CHANGE
Cash From Operating Activities	-$1.941M	1.740M	$14.42M
Cash From Investing Activities	-$148.0K	-3.121M	-$8.417M
Cash From Financing Activities	-$48.00K	-53.00K	-$230.0K
Net Change In Cash	-$2.156M	-1.434M	$5.796M
YoY Change	104.55%	807.59%	-829.97%
FREE CASH FLOW
Cash From Operating Activities	-$1.941M	$1.740M	$14.42M
Capital Expenditures	$148.0K	$119.0K	$566.0K
Free Cash Flow	-$2.089M	$1.621M	$13.85M
YoY Change	385.81%	-32.99%	87.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000839087
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185435965	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175127878	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10308087	shares
CY2020Q2	vaso	Capital Stock Sale To Subsidiaryrate CapitalStockSaleToSubsidiaryrate	0.51	pure
CY2015Q1	vaso	Company Ownership Rate CompanyOwnershipRate	0.499	pure
CY2021Q4	vaso	Contract With Customer Liability Post Delivery Services And Varying Duration Service ContractWithCustomerLiabilityPostDeliveryServicesAndVaryingDurationService	9000000	usd
CY2021	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	1100000.0	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.019	pure
CY2021Q4	vaso	Statutory Reserves StatutoryReserves	35000000	usd
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Authorized In Period Available For Future Issuance Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorizedInPeriodAvailableForFutureIssuanceAuthorized	0	shares
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Authorized In Period Available For Future Issuance Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorizedInPeriodAvailableForFutureIssuanceAuthorized	0	shares
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Vested Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceVestedNumberOfShares	0	shares
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Vested Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceVestedNumberOfShares	0	shares
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Forfeited Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceForfeitedNumberOfShares	0	shares
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Expired Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceExpiredNumberOfShares	0	shares
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Expired Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceExpiredNumberOfShares	0	shares
CY2021	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Authorized Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAuthorizedNumberOfShares	0	shares
CY2022	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Authorized Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAuthorizedNumberOfShares	0	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2021	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Expired Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares	0	shares
CY2022	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Expired Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares	0	shares
CY2019Q2	vaso	Employment Agreement Term EmploymentAgreementTerm	P5Y
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-18105
CY2022	dei	Entity Registrant Name EntityRegistrantName	VASO CORPORATION
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2871434
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	137 Commercial Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Plainview
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11803
CY2022	dei	City Area Code CityAreaCode	516
CY2022	dei	Local Phone Number LocalPhoneNumber	997-4600
CY2022	dei	Security12g Title Security12gTitle	Common Stock, $.001 par value
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	8700000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	175127878	shares
CY2022	dei	Auditor Firm AuditorFirmId	1195
CY2022	dei	Auditor Name AuditorName	UHY LLP
CY2022	dei	Auditor Location AuditorLocation	Sterling Heights, Michigan
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11821000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6025000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	8504000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	629000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6947000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5804000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15524000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15393000	usd
CY2022Q4	vaso	Receivables Due From Related Parties ReceivablesDueFromRelatedParties	421000	usd
CY2021Q4	vaso	Receivables Due From Related Parties ReceivablesDueFromRelatedParties	66000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1473000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147000	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	3249000	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	3549000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1008000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	994000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	42000000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	27803000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9787000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10512000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1340000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2172000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1568000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	915000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	15614000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	15722000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1511000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2041000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4726000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2446000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	889000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	1043000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	5007000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	219000	usd
CY2022Q4	us-gaap	Assets Assets	72655000	usd
CY2021Q4	us-gaap	Assets Assets	52361000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2270000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2797000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	3720000	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2705000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8891000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7489000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	122000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	222000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	562000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	809000	usd
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	719000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15139000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16495000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2022Q4	vaso	Due To Related Party Current DueToRelatedPartyCurrent	3000	usd
CY2021Q4	vaso	Due To Related Party Current DueToRelatedPartyCurrent	3000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31708000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31000000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	15000	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	23000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	96000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	218000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	823000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	352000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15664000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8470000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1474000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	988000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18072000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10051000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185435965	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175127878	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	185000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	185000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63952000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63917000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39029000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50902000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-233000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	110000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10308087	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22875000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11310000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72655000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52361000	usd
CY2022	vaso	Managed It Systems And Services ManagedItSystemsAndServices	40100000	usd
CY2021	vaso	Managed It Systems And Services ManagedItSystemsAndServices	42916000	usd
CY2022	vaso	Professional Sales Services ProfessionalSalesServices	37344000	usd
CY2021	vaso	Professional Sales Services ProfessionalSalesServices	29441000	usd
CY2022	vaso	Equipment Sales And Services EquipmentSalesAndServices	2573000	usd
CY2021	vaso	Equipment Sales And Services EquipmentSalesAndServices	3222000	usd
CY2022	us-gaap	Revenues Revenues	80017000	usd
CY2021	us-gaap	Revenues Revenues	75579000	usd
CY2022	vaso	Cost Of Managed It Systems And Services CostOfManagedItSystemsAndServices	23871000	usd
CY2021	vaso	Cost Of Managed It Systems And Services CostOfManagedItSystemsAndServices	26242000	usd
CY2022	vaso	Cost Of Professional Sales Services CostOfProfessionalSalesServices	7056000	usd
CY2021	vaso	Cost Of Professional Sales Services CostOfProfessionalSalesServices	5535000	usd
CY2022	vaso	Cost Of Equipment Sales And Services CostOfEquipmentSalesAndServices	609000	usd
CY2021	vaso	Cost Of Equipment Sales And Services CostOfEquipmentSalesAndServices	669000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31536000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32446000	usd
CY2022	us-gaap	Gross Profit GrossProfit	48481000	usd
CY2021	us-gaap	Gross Profit GrossProfit	43133000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40843000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38593000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	605000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1721000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	41448000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	40314000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	7033000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2819000	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	44000	usd
CY2021	us-gaap	Financing Interest Expense FinancingInterestExpense	312000	usd
CY2022	vaso	Interest And Other Income Expense InterestAndOtherIncomeExpense	143000	usd
CY2021	vaso	Interest And Other Income Expense InterestAndOtherIncomeExpense	98000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3646000	usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-2000	usd
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	97000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3432000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7130000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6251000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4743000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	151000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11873000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6100000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-343000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	94000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11530000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6194000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173065	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	171688	shares
CY2022	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	174656	shares
CY2021	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	173771	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5085000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	31000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	94000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6100000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11310000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11310000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-343000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11873000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22875000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-11873000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-6100000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1923000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3840000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4788000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	52000	usd
CY2022	vaso	Gain Loss From Investment In Eecp Global GainLossFromInvestmentInEecpGlobal	154000	usd
CY2021	vaso	Gain Loss From Investment In Eecp Global GainLossFromInvestmentInEecpGlobal	73000	usd
CY2022	vaso	Debt Instrument Decrease Forgiveness1 DebtInstrumentDecreaseForgiveness1	0	usd
CY2021	vaso	Debt Instrument Decrease Forgiveness1 DebtInstrumentDecreaseForgiveness1	3646000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	63000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	448000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	385000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	31000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	243000	usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6052000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	343000	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	46000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	416000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-299000	usd
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-300000	usd
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1195000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	103000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-162000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2422000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	212000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-521000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3492000	usd
CY2022	vaso	Increase Decrease In Accrued Commissions IncreaseDecreaseInAccruedCommissions	1094000	usd
CY2021	vaso	Increase Decrease In Accrued Commissions IncreaseDecreaseInAccruedCommissions	1497000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1392000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2372000	usd
CY2022	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	108000	usd
CY2021	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	94000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5838000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7260000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-14000	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-233000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	486000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	78000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14416000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7815000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	566000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	415000	usd
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	8000000	usd
CY2021	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	usd
CY2022	vaso	Redemption Of Short Term Investments RedemptionOfShortTermInvestments	149000	usd
CY2021	vaso	Redemption Of Short Term Investments RedemptionOfShortTermInvestments	155000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8417000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-260000	usd
CY2022	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-5448000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	230000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2881000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-230000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8329000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-20000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5796000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-794000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6025000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6819000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11821000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6025000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	44000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	347000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	48000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	35000	usd
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueemployees ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueemployees	14000000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	113000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1396000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	783000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">NOTE A – DESCRIPTION OF BUSINESS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP<sup style="vertical-align:super">®</sup>, therapy systems, mainly for the treatment of angina. In 2010 it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business mixture, and continues to use the original name VasoMedical for its proprietary medical device subsidiary. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Overview</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare (“GEHC”) into the health provider middle market; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>VasoTechnology</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">VasoTechnology, Inc.<em> </em>was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division, NetWolves, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In June 2014, the Company began its IT segment business by executing the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support. This business focuses primarily on customer segments currently served by VasoHealthcare on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business. The VAR Agreement with GEHC was terminated in 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2015, the Company further expanded its IT segment business by acquiring NetWolves. NetWolves designs and delivers multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>VasoHealthcare</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as its exclusive representative for the sale of select GEHC diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The original agreement (“GEHC Agreement”) has been extended several times and currently expires December 31, 2026, subject to earlier termination under certain conditions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>VasoMedical</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP<sup style="vertical-align:super">®</sup>) technology in the United States and has since diversified to include other medical hardware and software. Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Over the last decade the Company’s Equipment business has been significantly expanded from the original EECP<sup style="vertical-align:super">®</sup>-only operations. In September 2011, the Company acquired Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”) - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone, and in March 2019 Gentone exercised its option to acquire all of the shares of Biox. In August 2014, the Company, through Gentone, acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), which was formed in China in 2010 to develop the MobiCare<sup style="vertical-align:super">®</sup> wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox™ series ambulatory patient monitoring systems, ARCS<sup style="vertical-align:super">®</sup> series software for ECG and blood pressure analysis, and the MobiCare<sup style="vertical-align:super">®</sup> patient monitoring device. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In April 2014, the Company entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China, the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology. The Company owned 49.9% of VSK, which commenced operations in January 2015. In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK. On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to PSK. EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed a Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. The agreement provides an initial term of three years starting April 1, 2020, the effective date of the sale, which is automatically renewable for additional one-year terms. Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a monthly management fee during the term of the agreement.</p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commission adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock-based compensation, values and lives assigned to acquired intangible assets, fair value of reporting units in connection with goodwill impairment test, the adequacy of inventory reserves, variable consideration, and allocation of contract transaction price to performance obligations. Actual results could differ from those estimates.</p>
CY2022Q4	vaso	Revenue Remaining Performance Obligation Next Tewelve Year RevenueRemainingPerformanceObligationNextTewelveYear	41882	usd
CY2022Q4	vaso	Revenue Remaining Performance Obligation Second Year RevenueRemainingPerformanceObligationSecondYear	14496	usd
CY2022Q4	vaso	Revenue Remaining Performance Obligation Three Year RevenueRemainingPerformanceObligationThreeYear	4464	usd
CY2022Q4	vaso	Revenue Remaining Performance Obligation Thereafter RevenueRemainingPerformanceObligationThereafter	29697	usd
CY2022Q4	vaso	Transaction Price TransactionPrice	86000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	481000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	407000000	usd
CY2022Q4	vaso	Contract With Customer Liability For Acceptances Of Equipment ContractWithCustomerLiabilityForAcceptancesOfEquipment	30794000000	usd
CY2021Q4	vaso	Contract With Customer Liability For Acceptances Of Equipment ContractWithCustomerLiabilityForAcceptancesOfEquipment	24955000000	usd
CY2022Q4	vaso	Contract With Customer Liability For Customer Order Reductions ContractWithCustomerLiabilityForCustomerOrderReductions	2577000000	usd
CY2021Q4	vaso	Contract With Customer Liability For Customer Order Reductions ContractWithCustomerLiabilityForCustomerOrderReductions	1518000000	usd
CY2022Q4	vaso	Contract With Customer Liability Post Delivery Services And Varying Duration Service ContractWithCustomerLiabilityPostDeliveryServicesAndVaryingDurationService	9000000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9100000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5800000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
CY2022Q4	vaso	Amount Expensed Of Asset AmountExpensedOfAsset	2732000	usd
CY2021Q4	vaso	Amount Expensed Of Asset AmountExpensedOfAsset	1928000	usd
CY2022	vaso	Selling General And Administrative Expenses SellingGeneralAndAdministrativeExpenses	79000000	usd
CY2021	vaso	Selling General And Administrative Expenses SellingGeneralAndAdministrativeExpenses	120000000	usd
CY2022Q4	vaso	Capitalized Sales Commissions CapitalizedSalesCommissions	7113000000	usd
CY2021Q4	vaso	Capitalized Sales Commissions CapitalizedSalesCommissions	5567000000	usd
CY2022Q4	vaso	Deferred Commission Expense DeferredCommissionExpense	3249000000	usd
CY2021Q4	vaso	Deferred Commission Expense DeferredCommissionExpense	3549000000	usd
CY2022Q4	vaso	Longterm Portion LongtermPortion	3864000000	usd
CY2021Q4	vaso	Longterm Portion LongtermPortion	2018000000	usd
CY2022Q4	vaso	Consideration For Previously Completed Performance Obligations ConsiderationForPreviouslyCompletedPerformanceObligations	-5000000	usd
CY2021Q4	vaso	Consideration For Previously Completed Performance Obligations ConsiderationForPreviouslyCompletedPerformanceObligations	40000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1050000	shares
CY2022Q4	vaso	Restricted Common Stock Value RestrictedCommonStockValue	115000	usd
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueofficers ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueofficers	23000000	usd
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueemployees ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueemployees	4000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.11
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	90000	shares
CY2021Q4	vaso	Restricted Common Stock Value RestrictedCommonStockValue	4500	usd
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueofficers ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueofficers	23000000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	31000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	8071000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	8064000	usd
CY2022	vaso	Trading Securities Unrealized Holding Loss Amount TradingSecuritiesUnrealizedHoldingLossAmount	7000	usd
CY2022Q4	us-gaap	Deposits Fair Value Disclosure DepositsFairValueDisclosure	433000	usd
CY2022Q4	vaso	Fair Value Cash Equivalents In Money Market Funds FairValueCashEquivalentsInMoneyMarketFunds	7934	usd
CY2022Q4	vaso	Fair Value Bank Deposits In Short Term Investments FairValueBankDepositsInShortTermInvestments	433	usd
CY2022Q4	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	8367	usd
CY2021Q4	vaso	Fair Value Cash Equivalents In Money Market Funds FairValueCashEquivalentsInMoneyMarketFunds	802	usd
CY2021Q4	vaso	Fair Value Bank Deposits In Short Term Investments FairValueBankDepositsInShortTermInvestments	629	usd
CY2021Q4	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	1431	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5804000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4208000	usd
CY2022	vaso	Provision For Losses On Accounts Receivable ProvisionForLossesOnAccountsReceivable	63000	usd
CY2021	vaso	Provision For Losses On Accounts Receivable ProvisionForLossesOnAccountsReceivable	132000	usd
CY2022	vaso	Allowance For Doubtful Accounts Receivable Charge Offs Net Of Recoveries AllowanceForDoubtfulAccountsReceivableChargeOffsNetOfRecoveries	159000	usd
CY2021	vaso	Allowance For Doubtful Accounts Receivable Charge Offs Net Of Recoveries AllowanceForDoubtfulAccountsReceivableChargeOffsNetOfRecoveries	-77000	usd
CY2022	vaso	Allowance For Doubtful Accounts Receivable Commission Adjustment AllowanceForDoubtfulAccountsReceivableCommissionAdjustment	1239000	usd
CY2021	vaso	Allowance For Doubtful Accounts Receivable Commission Adjustment AllowanceForDoubtfulAccountsReceivableCommissionAdjustment	1541000	usd
CY2022	vaso	Allowancefordoubtful Accountsandcommissionadjustmentsending AllowancefordoubtfulAccountsandcommissionadjustmentsending	6947000	usd
CY2021	vaso	Allowancefordoubtful Accountsandcommissionadjustmentsending AllowancefordoubtfulAccountsandcommissionadjustmentsending	5804000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">We market our equipment and IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years ended December 31, 2022 and 2021, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable. In our professional sales service segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position and our long history of doing business with GEHC. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company maintains cash balances in certain U.S. financial institutions, which, at times, may exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000. The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $1,234,000 and $903,000 at December 31, 2022 and 2021, respectively.</p>
CY2022	vaso	Customer Accountabilityfor Revenues Or Accounts Receivable CustomerAccountabilityforRevenuesOrAccountsReceivable	0.10	pure
CY2022	vaso	Revenues And Accounts Receivable Are With Gehc RevenuesAndAccountsReceivableAreWithGehc	1	pure
CY2022Q4	vaso	Fdic Coverage Exceed FdicCoverageExceed	250000000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1234000000	usd
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	903000000	usd
CY2021	vaso	Longlived Assets To Be Impairedimpairments LonglivedAssetsToBeImpairedimpairments	324000000	usd
CY2022	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Amounts billable under the agreement with GEHC in advance of delivery of the underlying equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In our equipment segment, we record revenue on extended service contracts ratably over the term of the related service contracts. </p>
CY2022	vaso	Deferred Tax Asset Realized DeferredTaxAssetRealized	0.50	pure
CY2022	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	-343000000	usd
CY2021	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	94000000	usd
CY2022	vaso	Weighted Average Number Of Shares Outstanding Basic1 WeightedAverageNumberOfSharesOutstandingBasic1	173065000	shares
CY2021	vaso	Weighted Average Number Of Shares Outstanding Basic1 WeightedAverageNumberOfSharesOutstandingBasic1	171688000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1591000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2083000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174656000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173771000	shares
CY2022	us-gaap	Revenues Revenues	80017000	usd
CY2021	us-gaap	Revenues Revenues	75579000	usd
CY2022	us-gaap	Gross Profit GrossProfit	48481000	usd
CY2021	us-gaap	Gross Profit GrossProfit	43133000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	7033000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2819000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1923000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3840000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	566000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	415000	usd
CY2022Q4	us-gaap	Assets Assets	72655000	usd
CY2021Q4	us-gaap	Assets Assets	52361000	usd
CY2022	us-gaap	Revenues Revenues	80017000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22471000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21197000	usd
CY2022Q4	vaso	Allowance For Doubtful Accounts And Commission Adjustments AllowanceForDoubtfulAccountsAndCommissionAdjustments	6947000	usd
CY2021Q4	vaso	Allowance For Doubtful Accounts And Commission Adjustments AllowanceForDoubtfulAccountsAndCommissionAdjustments	5804000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15524000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15393000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	751000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	744000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	716000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	399000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1473000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	163000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	165000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11127000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12684000	usd
CY2022Q4	vaso	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment1	9787000	usd
CY2021Q4	vaso	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment1	10512000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1340000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2172000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	858000000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	833000000	usd
CY2022	us-gaap	Depreciation Depreciation	1372000000	usd
CY2021	us-gaap	Depreciation Depreciation	1868000000	usd
CY2022Q4	vaso	Goodwills Goodwills	14375000	usd
CY2021Q4	vaso	Goodwills Goodwills	1239000	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	15722000	usd
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	15688000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-108000	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	34000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	15614000	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	15722000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1511000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2041000	usd
CY2022	vaso	Disposal Of Asset And Accumulated Amount DisposalOfAssetAndAccumulatedAmount	1117000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	551000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1972000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	343000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	274000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	203000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	148000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	543000	usd
CY2021Q4	vaso	Finite Lived Intangible Assets Amortization Expense FiniteLivedIntangibleAssetsAmortizationExpense	1511000	usd
CY2022Q4	vaso	Deferred Commission Expense Noncurrent DeferredCommissionExpenseNoncurrent	3864000	usd
CY2021Q4	vaso	Deferred Commission Expense Noncurrent DeferredCommissionExpenseNoncurrent	2018000	usd
CY2022Q4	vaso	Trade Receivables Noncurrent TradeReceivablesNoncurrent	792000	usd
CY2021Q4	vaso	Trade Receivables Noncurrent TradeReceivablesNoncurrent	368000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	60000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4726000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2446000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	24965000	usd
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	17704000	usd
CY2022Q4	vaso	Deferred Revenue Ending DeferredRevenueEnding	30803000	usd
CY2021Q4	vaso	Deferred Revenue Ending DeferredRevenueEnding	24965000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15139000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16495000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15664000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8470000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2652000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2397000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2012000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1799000	usd
CY2022Q4	vaso	Order Reduction Liability OrderReductionLiability	2577	usd
CY2021Q4	vaso	Order Reduction Liability OrderReductionLiability	1518	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	1650000	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	1775000	usd
CY2022Q4	vaso	Accrued Expenses And Other Liabilities AccruedExpensesAndOtherLiabilities	8891000	usd
CY2021Q4	vaso	Accrued Expenses And Other Liabilities AccruedExpensesAndOtherLiabilities	7489000	usd
CY2022	us-gaap	Interest Costs Incurred InterestCostsIncurred	0	usd
CY2021	us-gaap	Interest Costs Incurred InterestCostsIncurred	131000000	usd
CY2022	us-gaap	Legal Fees LegalFees	95000	usd
CY2021	us-gaap	Legal Fees LegalFees	190000	usd
CY2022Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	24000	usd
CY2021Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	31000	usd
CY2022Q4	us-gaap	Debt Current DebtCurrent	9000	usd
CY2021Q4	us-gaap	Debt Current DebtCurrent	8000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	15000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	23000	usd
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.019	pure
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	3000000.0	usd
CY2022Q4	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2023-08-31
CY2022	vaso	Lease Assets And Liabilities For Leases Term LeaseAssetsAndLiabilitiesForLeasesTerm	P12Y
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	122000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	222000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	562000	usd
CY2022Q4	vaso	Lease Liabilities Current LeaseLiabilitiesCurrent	867000	usd
CY2021Q4	vaso	Lease Liabilities Current LeaseLiabilitiesCurrent	784000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	96000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	218000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	823000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	352000	usd
CY2022Q4	vaso	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	919000	usd
CY2021Q4	vaso	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	570000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	144000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	782000	usd
CY2022Q4	vaso	Lease Liability Payments Due Next Twelve Months LeaseLiabilityPaymentsDueNextTwelveMonths	926000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	83000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	554000	usd
CY2022Q4	vaso	Lease Liability Payments Due Year Two LeaseLiabilityPaymentsDueYearTwo	637000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	25000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	324000	usd
CY2022Q4	vaso	Lease Liability Payments Due Year Three LeaseLiabilityPaymentsDueYearThree	349000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	71000	usd
CY2022Q4	vaso	Lease Liability Payments Due Year Four LeaseLiabilityPaymentsDueYearFour	71000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	252000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1731000	usd
CY2022Q4	vaso	Lease Liability Payments Due LeaseLiabilityPaymentsDue	1983000	usd
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	34000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	163000	usd
CY2022Q4	vaso	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	-197000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	218000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1568000	usd
CY2022Q4	vaso	Lease Liability LeaseLiability	1786000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	154000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	193000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	44000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	45000	usd
CY2022	vaso	Finance Lease Cost FinanceLeaseCost	198000	usd
CY2021	vaso	Finance Lease Cost FinanceLeaseCost	238000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	878000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	792000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	52000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	78000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1128000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1108000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	44000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	45000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	792000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	222000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	199000	usd
CY2022	vaso	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	1144000	usd
CY2021	vaso	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	1036000	usd
CY2022	vaso	Weighted Average Remaining Lease Term Finance Leases WeightedAverageRemainingLeaseTermFinanceLeases	P23Y
CY2021	vaso	Weighted Average Remaining Lease Term Finance Leases WeightedAverageRemainingLeaseTermFinanceLeases	P28Y
CY2022	vaso	Weighted Average Remaining Lease Term Operating Leases WeightedAverageRemainingLeaseTermOperatingLeases	P30Y
CY2021	vaso	Weighted Average Remaining Lease Term Operating Leases WeightedAverageRemainingLeaseTermOperatingLeases	P25Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.142	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.131	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088	pure
CY2022	vaso	Withholding Taxrate WithholdingTaxrate	0.10	pure
CY2022	vaso	Reserves Reaches Rate ReservesReachesRate	0.50	pure
CY2022Q4	vaso	Statutory Reserves StatutoryReserves	35000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	11005580	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4391666	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.02
CY2021	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Authorized Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAuthorizedWeightedAverageGrantDateFairValue	0
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Available For Future Issuance Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAvailableForFutureIssuanceGross	-90000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	90000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1491666	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.02
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2021	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10915580	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2990000	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.02
CY2022	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Authorized Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAuthorizedWeightedAverageGrantDateFairValue	0
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Available For Future Issuance Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAvailableForFutureIssuanceGross	-1050000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1050000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.11
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1300000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.02
CY2022	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Forfeited Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceForfeitedNumberOfShares	90000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	90000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.05
CY2022	vaso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	9955580	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2650000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.06
CY2022Q4	vaso	Common Stock Shares Authorized1 CommonStockSharesAuthorized1	53558455	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6823000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5720000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	307000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	531000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7130000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6251000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0020	pure
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	36000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	47000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	52000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	45000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	99000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3724000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	41000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1064000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-4788000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	52000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4743000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	151000	usd
CY2022	vaso	Effective Income Tax Rate EffectiveIncomeTaxRate	-0.6652	pure
CY2021	vaso	Effective Income Tax Rate EffectiveIncomeTaxRate	0.0242	pure
CY2022	vaso	Income Tax Expense Benefit1 IncomeTaxExpenseBenefit1	9000000	usd
CY2021	vaso	Income Tax Expense Benefit1 IncomeTaxExpenseBenefit1	151000000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	52000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0613	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0270	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.8730	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2132	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0078	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0084	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0054	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0008	pure
CY2022	vaso	Ppp Loan Forgiveness PPPLoanForgiveness	0	pure
CY2021	vaso	Ppp Loan Forgiveness PPPLoanForgiveness	-0.1187	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0631	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.1277	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.6652	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0242	pure
CY2022Q4	vaso	Deferred Tax Assets Gross1 DeferredTaxAssetsGross1	12006000000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1099000000	usd
CY2022Q4	vaso	Deferred Tax Assets Valuation Allowance1 DeferredTaxAssetsValuationAllowance1	4543000000	usd
CY2022	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	6226000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8367000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10015000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	328000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	343000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	7000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	5000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	99000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	125000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	46000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	47000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	416000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	454000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	908000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	786000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1835000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1330000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12006000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13105000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4543000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7463000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2336000	usd
CY2022Q4	vaso	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	-464000	usd
CY2021Q4	vaso	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	-325000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1962000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1703000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	30000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	89000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2456000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2117000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5007000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	219000	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	5007000	usd
CY2021Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	219000	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Liabilities Noncurrent DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent	0	usd
CY2021Q4	us-gaap	Deferred Income Taxes And Other Liabilities Noncurrent DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent	0	usd
CY2022Q4	vaso	Deferred Tax Liabilities1 DeferredTaxLiabilities1	5007000	usd
CY2021Q4	vaso	Deferred Tax Liabilities1 DeferredTaxLiabilities1	219000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12145000	usd
CY2022	us-gaap	Allowance For Loan And Lease Losses Write Offs AllowanceForLoanAndLeaseLossesWriteOffs	-4840000	usd
CY2021	us-gaap	Allowance For Loan And Lease Losses Write Offs AllowanceForLoanAndLeaseLossesWriteOffs	0	usd
CY2022	vaso	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance1 IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance1	1386000	usd
CY2021	vaso	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance1 IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance1	1376000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4543000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24000000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	7000000	usd
CY2017Q4	vaso	Number Of States For Market Segments And Accounts NumberOfStatesForMarketSegmentsAndAccounts	48	integer
CY2019Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	500000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	350000	usd
CY2022	vaso	Licensing And Support Service LicensingAndSupportService	339000	usd
	vaso	Licensing And Support Service LicensingAndSupportService	343000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	112000000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	129000000	usd

Files In Submission

Name	View Source	Status
0001654954-23-004142-index-headers.html	Edgar Link	pending
0001654954-23-004142-index.html	Edgar Link	pending
0001654954-23-004142.txt	Edgar Link	pending
0001654954-23-004142-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vaso-20221231.xsd	Edgar Link	pending
vaso_10k.htm	Edgar Link	pending
vaso_10kimg1.jpg	Edgar Link	pending
vaso_ex311.htm	Edgar Link	pending
vaso_ex312.htm	Edgar Link	pending
vaso_ex321.htm	Edgar Link	pending
vaso_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
vaso-20221231_lab.xml	Edgar Link	unprocessable
vaso-20221231_cal.xml	Edgar Link	unprocessable
vaso-20221231_def.xml	Edgar Link	unprocessable
vaso-20221231_pre.xml	Edgar Link	unprocessable
vaso_10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VASO
VASO Corp Stock $vaso

2023 Q1 Form 10-K Financial Statement

#000165495423004142 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VASO VASO Corp Stock $vaso

2023 Q1 Form 10-K Financial Statement

#000165495423004142 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VASO
VASO Corp Stock $vaso